Buddlejasaponin I
Buddlejasaponin I (Verbascosaponin B) is an inhibitor of COX and 5-LOX. Buddlejasaponin I inhibits the production of COX metabolites PGE2, TXB2, and the 5-LOX metabolite LTC4. Buddlejasaponin I reduces ear swelling in mice. Buddlejasaponin I is applicable to inflammation-related research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 139501-36-3
- Formule: C54H88O22
- Masse moléculaire:1089.26
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
[1]|
5-LOX |
In Vitro
Buddlejasaponin I potently inhibits LTC4 release from mouse peritoneal macrophages stimulated by the calcium ionophore A23187 (HY-N6687), with an IC50 of 2.4 μM and a 100% inhibition rate at a concentration of 100 μM[1].
Buddlejasaponin I slightly inhibits the release of PGE2 from mouse peritoneal macrophages stimulated by calcium ionophore A23187, with an IC50 of 93 μM and an inhibition rate of 40.4% at a concentration of 100 μM[1].
Buddlejasaponin I inhibits TXB2 release from human platelets stimulated by the calcium ionophore A23187, with an IC50 of 27 μM and an inhibition rate of 76.7% at a concentration of 100 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss mice (female, 8 weeks old)[1]
-
Dosage:1 mg/ear
-
Administration:topical; single dose
-
Result:Achieved 94.41% inhibition of PMA-induced ear edema at 3 hours post-PMA.
Exerted only 2.99% inhibition of PMA-induced vascular permeability, which was not a significant effect.
Chemical Information
-
CAS No. 139501-36-3
-
Masse moléculaire 1089.26
-
Formule C54H88O22
-
SMILES
C[C@]12[C@]3(C=C[C@@]4([H])[C@]2(CC[C@]5([H])[C@@]4(CC[C@@H]([C@@]5(C)CO)O[C@H]6[C@@H]([C@H]([C@H]([C@H](O6)C)O)O[C@@H]7O[C@@H]([C@H]([C@@H]([C@H]7O)O)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)CO)O[C@@H]9O[C@@H]([C@H]([C@@H]([C@H]9O)O)O)CO)C)C)C%10([H])[C@@]([C@H](C1)O)(CCC(C)(C%10)C)CO3
-
Synonyms
Verbascosaponin B
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Buddlejasaponin I Related Classifications
HY-N19723 Related Classifications
Powered by Bioz